Skip to main content
. 2021 Feb 18;12:636324. doi: 10.3389/fphar.2021.636324

TABLE 4.

Pharmacokinetic (PK) properties of M5 after oral administration of single and multiple doses of 50-, 100-, 150-, 220-, 300-, 350- and 400-mg larotinib mesylate tablets.

PK Variables Dosage (mg)
50 mg 100 mg 150 mg 220 mg 300 mg 350 mg 400 mg
Single oral administration No 3 3 3 3 6 3 3
Tmax, median (min–max), h 6.00 (1.00–6.00) 6.00 (5.00–12.00) 3.00 (2.00–9.00) 3.00 (2.00–9.00) 6.00 (2.00–12.00) 3.00 (2.00–6.00) 3.00 (2.00–12.00)
Cmax, mean (min–max), ng/mL 11.826 (5.276–20.72) 35.75 (5.310–72.28) 49.09 (8.958–91.24) 28.19 (19.05–42.48) 114.7 (32.69–191.0) 80.07 (67.58–94.76) 120.3 (78.46–200.6)
AUC0-24, mean ((min-max)), h*ng/mL 203.8 (113.5–356.8) 474.5 (93.34–887.0) 575.5 (167.6–1,039) 425.5 (205.8–638.6) 1,323 (386.9–2,681) 978.2 (888.5–1,036) 1,646 (1,043–2,450)
AUC0-t, mean ((min-max)), h*ng/mL 515.4 (342.1–724.1) 860.4 (223.7–1,612) 1,195 (583.5–1842) 803.7 (476.8–1,096) 2,440 (674.1–4,640) 1986 (1871–2091) 3,612 (1774–4,733)
AUC0-∞, mean ((min-max)), h*ng/mL 626.1 (367.5–765.6) 920.8 (256.5–1714) 1,347 (760.0–1916) 949.6 (558.0–1,306) 2,616 (705.5–5,111) 2096 (1980–2,212) 4,284 (1956–5,553)
T1/2, mean ((min-max)), h 46.92 (24.98–88.00) 37.21 (33.32–41.31) 41.01 (26.43–59.33) 64.24 (41.98–75.88) 32.64 (23.25–44.17) 28.57 (26.44–32.64) 48.40 (40.13–53.58)
Vz/F, mean ((min-max)), L 5,346 (2,617–8,519) 9,654 (3,477–18,742) 8,598 (2,986–16,894) 22,148 (18,438–24,125) 8,096 (2,580–15,907) 6,925 (6,036–8,322) 7660 (5,352–11,839)
CL/F, mean ((min-max)), L/h 89.47 (65.30–136.0) 191.5 (58.33–389.9) 128.6 (78.30–197.4) 262.0 (168.4–394.3) 178.3 (58.70–425.2) 167.3 (158.2–176.7) 117.1 (72.04–204.5)
Multiple oral administration No 3 3 3 3 5 3 3
Tmax,ss, median (min–max), h 9.00 (1.00–12.00) 5.00 (5.00–24.00) 5.00 (5.00–5.00) 6.00 (6.00–12.00) 6.00 (0.00–12.00) 5.00 (2.00–6.00) 5.00 (3.00–6.00)
Cmax,ss, mean ((min-max)), ng/mL 44.94 (42.31–46.50) 110.3 (46.48–187.0) 242.4 (79.13–365.4) 185.4 (123.2–291.1) 230.9 (41.74–516.1) 353.4 (159.3–503.1) 752.0 (212.5–1,511)
AUCτ,ss, mean ((min-max)), h*ng/mL 788.7 (681.9–874.4) 1,356 (539.7–2,272) 4,221 (1,269–6,440) 3,128 (2,117–4,796) 4,092 (701.6–8,440) 5,852 (2,497–10,089) 9,572 (3,610–16,790)
AUC0-t,ss, mean ((min-max)), h*ng/mL 2,332 (1863–2,725) 2,737 (1,320–4,450) 12,043 (3,445–17,143 7998 (4,661–13,758) 10,114 (2,229–22,840) 14,576 (11,235–19,076) 22,565 (12,430–32,554)
AUC0-∞,ss, mean ((min-max)), h*ng/mL 3,057 (2,170–3,835) 3,077 (1,643–4,952) 13,510 (4,714–19,002) 13,661 (6,569–27,809) 15,385 (2,328–38,578) 16,911 (14,280–20,484) 40,022 (31,831–51,472)
T1/2,ss, mean ((min-max)), h 53.79 (35.79–84.19) 47.38 (35.09–65.09) 38.79 (30.91–53.13) 89.40 (49.83–124.7) 70.75 (28.95–95.37) 36.94 (31.47–44.32) 151.3 (38.91–346.4)
Vz/F,ss, mean ((min-max)), L 1,258 (815.5–1,584) 3,011 (1,022–5,716) 1,068 (368.2–2,439) 2,777 (1,423–4,501) 3,861 (1,070–8,728) 1,150 (775.7–1,567) 1912 (610.8–3,883)
CL/F,ss, mean ((min-max)), L/h 17.29 (13.04–23.04) 39.66 (20.19–60.87) 16.21 (7.894–31.82) 24.90 (7.911–33.49) 48.76 (7.777–128.8) 21.17 (17.09–24.51) 10.41 (7.771–12.57)
R1 (min-max) 5.08 (1.911–7.136) 3.73 (2.561–5.782) 7.77 (6.197–9.527) 8.140 (4.899–12.01) 3.882 (0.7928–6.478) 5.94 (2.473–9.743) 7.327 (2.499–16.09)
R2 (min-max) 5.048 (2.221–8.020) 4.874 (2.587–8.753) 6.282 (4.005–8.833) 6.549 (5.346–7.447) 2.255 (0.7851–4.025) 4.477 (2.358–5.762) 8.171 (2.597–19.26)

ss, steady state; SD, standard deviation; Tmax, time to peak plasma concentration; Cmax, peak plasma concentration; AUC, area under the plasma concentration curve; T1/2, terminal elimination halt-life; Vz/F, apparent volume of distribution; CL/F, apparent clearance; R1, AUCτ,cycle1/AUC0–24h,cycle0; R2, Cmax, cycle1/Cmax, cycle0.